相关产品推荐更多 >

SARS-CoV-2 Spike S1+S2 (YH145-146 deletion, E484K, D614G) Protein (ECD, His Tag)
¥4500
SARS-CoV-2 Spike S1+S2 (T19R, L452R, E484Q, D614G, P681R, D950N, G142D) Protein (ECD, His Tag)
¥4500
Coronavirus Nucleocapsid重组蛋白|Recombinant SARS-CoV-2 (2019-nCoV) Nucleocapsid-His Recombinant Protein
¥4500
Coronavirus spike重组蛋白|Recombinant SARS-CoV-2 Spike S1+S2 ECD(D614G)-His Recombinant Protein
¥4500
DENV Envelope / DENV-E Protein (His Tag)
¥4520
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存:
99
- 英文名:
SARS-CoV-2 (2019-nCoV) Spike S1+S2 (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F) Protein (ECD, His Tag)
- 保质期:
12个月
- 供应商:
北京义翘神州科技股份有限公司
- 保存条件:
-20℃ to -80℃
- 规格:
100 µg
纯度> 90 % as determined by SDS-PAGE.
内毒素< 1.0 EU per μg protein as determined by the LAL method.
生物活性Testing in progress
蛋白构建A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike S1+S2 (YP_009724390.1, with mutations L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F) (Met1-Pro1213) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant P.1) which emerged in the Brazil.
表达宿主Baculovirus-Insect Cells
种属SARS-CoV-2
预测 N 端Val 16
分子量The recombinant SARS-CoV-2 (2019-nCoV) Spike S1+S2 consists of 1209 amino acids and predicts a molecular mass of 134.5 kDa.
缓冲液Lyophilized from sterile 20 mM Tris, 300 mM NaCl, 10 % glycerol, pH 8.0.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
运输方式In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
稳定性 & 储存条件Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
复溶A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验2, Li H, et al. Isolation of a human SARS-CoV-2 neutralizing antibody from a synthetic phage library and its conversion to fluorescent biosensors.Scientific reports, PubMed ID: 36109569
中科院高福院士课题组 2020 年发表了哪些重要的研究成果?
隆抗体 CB6 正式产品名为 JS016,目前已进入临床三期试验,前期数据表明能够有效治疗新冠轻中症感染患者。 图源:中科院微生物研究所 10、设计通用策略研发新冠病毒重组蛋白疫苗DOI: 10.1016/j.cell.2020.06.035疫苗可以说是解决新冠病毒蔓延最好的方式,新冠肺炎疫请发生后各国科学家都在争分夺秒地研究新冠疫苗,中国的疫苗研发也是一直处于世界前列。2020 年 8 月 6 日,高福院士联合严景华等在 Cell 杂志发文:A Universal Design
隆抗体的研制。与传统的动物免疫方法不同,杂交瘤技术可以产生针对特定抗原的高纯单克隆抗体,并可大量生产单克隆抗体。由于其极强的特异性,杂交瘤抗体技术已广泛应用于生物学、药学、医学等领域,具有极其广阔的应用前景。 普健生物杂交瘤抗体技术平台 1.免疫方式:多肽、重组蛋白(五大表达系统)、小分子和DNA免疫等多种方案 2.一站式服务:提供从基因序列到杂交瘤细胞开发及鉴定的整体解决方案 3.高效电融合技术:美国BTX公司ECM 2001电融合仪平台,高效、无毒 4.成功率高:单抗
尴尬:轰轰烈烈的新冠疫苗「研发成功」热潮,可能只是在画饼充饥...
公司 Moderna 宣布研制出针对新冠病毒的人体疫苗,并即将进行临床实验;2 月 25 日,天津大学生命科学学院黄金海教授团队宣布已成功研发出新型冠状病毒口服疫苗,目前正寻求合作方,推动疫苗早日走向临床;2 月 26 日,俄罗斯副总理称俄罗斯已经研制出 5 种 SARS-Cov-2 病毒原型疫苗;2 月 27 日,流行病应对创新联盟(CEPI)宣布,除 Moderna 外,将资助另两家机构 Inovio 和澳大利亚昆士兰大学研发 SARS-Cov-2 疫苗;2 月 28 日,以色列的一家研发机构声称
技术资料暂无技术资料 索取技术资料




